This article has Open Peer Review reports available.
Diagnostic challenges of early Lyme disease: Lessons from a community case series
- John Aucott1Email author,
- Candis Morrison†2,
- Beatriz Munoz†3,
- Peter C Rowe†4,
- Alison Schwarzwalder†2 and
- Sheila K West†3
© Aucott et al; licensee BioMed Central Ltd. 2009
Received: 30 December 2008
Accepted: 01 June 2009
Published: 01 June 2009
Lyme disease, the most common vector-borne infection in North America, is increasingly reported. When the characteristic rash, erythema migrans, is not recognized and treated, delayed manifestations of disseminated infection may occur. The accuracy of diagnosis and treatment of early Lyme disease in the community is unknown.
A retrospective, consecutive case series of 165 patients presenting for possible early Lyme disease between August 1, 2002 and August 1, 2007 to a community-based Lyme referral practice in Maryland. All patients had acute symptoms of less than or equal to 12 weeks duration. Patients were categorized according to the Centers for Disease Control and Prevention criteria and data were collected on presenting history, physical findings, laboratory serology, prior diagnoses and prior treatments.
The majority (61%) of patients in this case series were diagnosed with early Lyme disease. Of those diagnosed with early Lyme disease, 13% did not present with erythema migrans; of those not presenting with a rash, 54% had been previously misdiagnosed. Among those with a rash, the diagnosis of erythema migrans was initially missed in 23% of patients whose rash was subsequently confirmed. Of all patients previously misdiagnosed, 41% had received initial antibiotics likely to be ineffective against Lyme disease.
For community physicians practicing in high-risk geographic areas, the diagnosis of Lyme disease remains a challenge. Failure to recognize erythema migrans or alternatively, viral-like presentations without a rash, can lead to missed or delayed diagnosis of Lyme disease, ineffective antibiotic treatment, and the potential for late manifestations.
Lyme disease is a multisystem infection caused by the spirochete Borrelia burgdorferi sensu stricto in North America. With over 27,000 new cases reported yearly, Lyme disease is the most commonly reported vector-borne disease in the United States, with the number of reported cases more than doubling between 1992 and 2006 . Additional studies have shown that actual cases of Lyme disease may exceed reported cases by a factor of 6 to 12 in endemic areas [2, 3]. The hallmark of early disease is a localized skin infection, erythema migrans (EM), which occurs at the site of the bite of an infected tick. Accurate identification of this rash is essential to a correct diagnosis, as serology is negative in 60% of patients early in infection when initial evaluation is likely to occur . The ability of clinicians to accurately diagnose EM is unclear, but both over and under diagnosis have been reported [5, 6]. Additionally, some reports suggest that up to 10% of patients with acute Lyme disease do not have a rash . When untreated, the initial localized cutaneous infection may then spread hematogenously to other areas of the skin, nervous system, heart and joints.
2008 CDC Lyme Disease Surveillance Case Definition 
a. a case of EM with a known exposure *
b. a case of EM with laboratory evidence of infection and without a known exposure
c. a case with at least one late manifestation that has laboratory evidence of infection
Any other case of physician-diagnosed Lyme disease that has laboratory evidence of infection
a. a case of EM where there is no known exposure and no laboratory evidence of infection
b. a case with laboratory evidence of infection but no clinical information available (e.g. a laboratory report)
The recently revised CDC case definition of Lyme disease now includes "probable" and "suspected" case classifications (Table 1). Viral-like presentations without a rash, in conjunction with positive serology, can now be considered part of the clinical spectrum of B. burgdorferi infection . Such presentations did not meet prior CDC case definitions and only recently can be considered "probable Lyme disease" [8, 9]. It is unknown whether this presentation is widely recognized by the general medical community .
Accurate diagnosis of early Lyme disease is important, as delayed diagnosis, missed diagnosis, or inadequate treatment with non-recommended antibiotics may have serious sequelae. A previous treatment trial with azithromycin, an antibiotic not currently recommended as first-line therapy, showed a significantly higher rate of post-treatment complications when compared with amoxicillin, a currently recommended antibiotic . Further, persistent symptoms after treatment of early Lyme disease is well described and may be more common in patients with delayed diagnosis [17–19]. Estimating the incidence of post-treatment symptoms to be 5–15% and the number of new reported and unreported cases of Lyme disease to be between 160,000 and 320,000 cases a year predicts as many as 8,100 to 48,600 new patients with post treatment symptoms a year [18, 20, 21].
The objectives of this retrospective review are to characterize a group of community-based, ambulatory patients presenting for evaluation of possible early Lyme disease, to determine how many of these patients meet CDC criteria, and to characterize patterns of care and treatment for these patients. Few such reviews exist which address the translation of Lyme disease guidelines and recommendations to the community practice of medicine .
Patients and Setting
This review included consecutive patients presenting between August 1, 2002 and August 1, 2007 to a general internist with infectious disease training (JA) for possible early Lyme disease. Patients were either self or physician referred for consultation. The practice is located in Baltimore County, Maryland, a region characterized as high risk for Lyme disease.
A complete history and physical exam, including a total-body skin exam, were performed. If a skin rash meeting CDC criteria for EM was not seen, ELISA and western blot serologies for immunoglobulin M or immunoglobulin G antibodies was obtained. Extensive evaluation for possible alternative diagnoses was initiated if the patient did not have a diagnostic EM rash at the time of consultation, or if the medical history, physical exam or laboratory findings were suggestive. All subjective and objective signs and symptoms were documented on a standardized form, and any relevant medical records were reviewed. To assess neurologic involvement, documentation of cerebrospinal fluid analysis, central nervous system imaging, and nerve conduction studies was also reviewed. Patients also self-reported prior diagnoses, symptom explanations, and antibiotic and glucocorticosteroid use prior to presentation. Antibiotics considered ineffective for treatment of Lyme disease included 1st generation cephalosporins, quinolones, and short-course macrolides such as 5-day azithromycin "Z-packs" or 7–10 days of clarithromycin .
Definition of Cases
We included all patients referred with acute symptoms less than or equal to 12 weeks of duration. Where serologic confirmation was necessary, ELISA and Western Blots were performed by a generally available commercial lab and interpreted according to CDC criteria .
Confirmed early Lyme disease was defined by the CDC case definition , including either a) an EM rash or b) positive serology in the presence of an objective finding of cranial neuritis, meningitis, carditis or joint swelling. Clinical diagnosis of EM was made by a consulting physician (JA) with a high rate of specificity in EM diagnosis .
Probable early Lyme disease was defined by the recently adopted CDC case definition  as presentation with an acute illness, no physician-documented EM, and positive serologic confirmation, including the presence of both a positive ELISA and 2 or more bands on the IgM western blot.
Alternative acute presentations which did not meet criteria for early or probable early Lyme disease were further categorized into three groups.
a. Patients with specific, non-dermatologic diagnoses, including infections other than Lyme disease
b. Patients with dermatologic diagnoses
c. Patients with non-specific, viral-like syndromes without evidence of an alternative infectious process.
Case characteristics were analyzed using simple percentages and Fisher's exact tests.
This study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine and written, signed consent was obtained for all figures containing patient photographs.
Characteristics and presenting features of previously misdiagnosed patients (n = 27)
n = 88
n = 6
n = 7
n = 101
Patients with prior misdiagnosis (% of all patients in category)
Sero (+) for early Lyme disease
Exposed to ineffective antibiotic prior to diagnosis
Exposed to steroids prior to diagnosis
Of the 13 seropositive patients diagnosed with Lyme disease without an EM present, 7 (53.8%) had been previously misdiagnosed (Table 2). Misdiagnosis occurred with greater frequency in patients with no EM and extracutaneous, objective manifestations (83%) than in patients with EM (23%: p = 0.004). Prior diagnoses given to these misdiagnosed patients included diverticulitis, acute coronary syndrome, sciatica, and lymphoma. Of all misdiagnosed cases, 11 (41%) received an antibiotic not recommended for treatment of Lyme disease and 8 (30%) were exposed to steroids.
Sixty four patients with acute symptoms did not meet criteria for confirmed or probable early Lyme disease (Figure 1). Twenty-five of these patients (39%) presented with negative serology and an acute, viral-like illness without objective findings. When prior antibiotic exposure was assessed for these patients, 70% had received antibiotics before diagnostic serology was obtained, compared with none of the sero-positive patients presenting with similar symptoms (p = 0.002). In 17 of these 64 patients (25%), an alternative diagnosis was made, including parvovirus, Ramsay Hunt syndrome or varicella zoster virus. A final group of 22 patients (36%) had rashes failing criteria for EM who received other dermatologic diagnoses, including local hypersensitivity tick bite reactions, round lesions of small size, or urticaria.
In light of recently revised CDC guidelines, this review highlights three major challenges continuing to face community practitioners: first, accurate diagnosis of EM, second, the identification of viral-like illnesses without a rash as possible Lyme disease, and third, appropriate antibiotic selection in community settings where Lyme disease is prevalent.
Even when a suspicious rash is found, there is no single, independent element in the medical history or physical exam highly sensitive for confirming the diagnosis of EM, and the specificity of the finding is unclear . No confirmatory tests (such as PCR or culture) are available to community practitioners despite their potential utility in early diagnosis, and serologies offer a 60% false negative rate in the first weeks of infection [4, 24, 28]. Accurate diagnosis of EM requires an experienced clinical impression of the rash's appearance . EM may be missed if not specifically sought on exam, as they are often asymptomatic, unseen by the patient, and found in areas such as the back, trunk and groin. In our series, several patients with an eventual EM diagnosis either received an incomplete skin exam or had a delayed EM appearance. Misidentification of EM represents a serious problem in the community, as opportunities for accurate diagnoses and appropriate treatment wane after the rash disappears. Relying on patient history or incomplete examination can thus leave the physician without a hallmark of the disease.
The common misconception that a bull's eye EM is the only diagnostic manifestation of Lyme disease continues to mislead both patients and practitioners. The absence of EM for 13% of our early Lyme cases highlights this discrepancy, with the majority of these seropositive patients (54%) developing only non-specific, viral-like illnesses without objective manifestations. Little attention has been afforded this presentation, despite the recognition that it may account for up to 9–16% of all early cases [15, 29, 30]. However, the IDSA guidelines for the management of Lyme disease do not specifically address nor provide treatment options for this subset of patients  and they are not included in treatment trials or long term outcome studies [31, 32]. Our data suggests that 7% (95% CI: 2%–12%) of all acute cases may present with a viral-like illness and positive serology. Further, our identification of a subset of seronegative patients presenting with similar, non-specific viral-like illnesses of unknown etiology is notable. It is unclear whether a proportion of these patients represent probable cases who simply failed to meet current serological criteria. Until more effective antigen detection, PCR or culture become available, diagnosis of non-specific, viral-like illnesses in Lyme endemic areas will remain problematic. In high risk areas, clinicians need to be aware of such presentations in order to minimize misdiagnoses, missed treatment opportunities, and the overall population burden of Lyme disease.
Our patients with early Lyme disease defined by extracutanous, objective neurologic or cardiac disease often had systemic presentations with abdominal pain, chest symptoms or other atypical features. This misled clinicians to treat incorrect etiologies, including diverticulitis, acute coronary syndrome, sciatica, and lymphoma. Especially confusing are systemic presentations with elevated AST and ALT, previously reported in 37% of presenting patients [33, 34]. Chest or abdominal pain are uncommon but elusive presentations of Lyme disease that may be due to cardiac involvement or radiculopathy involving the thoracic dermatomes [35–37].
Among previously misdiagnosed early Lyme patients, 41% received ineffective antibiotics which have been associated with treatment failures and higher relapse rates [11, 12, 38]. For misdiagnosed patients or those presenting with a viral-like illness, administration of ineffective antibiotics may produce unintended consequences. In studies showing suboptimal results with azithromycin, patients were often seronegative after treatment , raising the potential impact of sub-optimal therapy on seroconversion and further complicating reliance on a serology-based diagnosis . In our series, seronegative patients presenting with a viral-like illness were significantly more likely to have been exposed to antibiotics prior to confirmatory serology than those who tested positive. The impact of ineffective antibiotics on early Lyme disease warrants further research.
The circumstances associated with steroid use in our series were a presentation of VII nerve palsy (presumably administered as treatment for idiopathic Bell's palsy) or a diagnosis of spider bite. It is unclear what additional impact the administration of steroids may have on the natural history of Lyme disease in humans , however steroid administration was shown to be required to achieve high rates of central nervous system infection in the Rhesus monkey model of neuroborreliosis .
This study has several limitations. Our inability to perform cultures or PCR on patient rashes left us without true diagnostic confirmation of the presence or absence of EM, particularly among those patients with atypical rashes. The percentage of patients with misdiagnosed rashes that showed serologic evidence of exposure to Borrelia burgdorferi (70%) is expected in the setting of early Lyme disease. Despite the expected level of seroreactivity, we can not be sure that the rashes we diagnosed were all due to Lyme disease. However, physicians in community practice currently do not have access to culture or PCR and must rely as we did on clinical experience when evaluating potential EM rashes. In addition, the referral population may be biased toward more complicated acute cases than are typically seen in a community population. Since patients were drawn exclusively from Maryland, results may not be generalizable to other regions where experience with Lyme diagnosis may be higher, or rates of co-infection with other tick-borne agents vary. Finally, focusing solely on those patients referred for possible acute Lyme disease fails to capture the complexity of addressing those patients referred with chronic symptoms and more complicated medical histories.
Until more accurate tests are developed for early Lyme disease, cases without a diagnostic EM rash will need to be managed carefully. In patients with cutaneous lesions where the differential diagnosis of cellulitis is not certain, empiric antibiotics should be chosen that will have activity against both Lyme disease and common agents of cellulitis . In patients with viral-like illness, the clinician has the option of obtaining acute and convalescent serologies without treatment, or treating empirically with doxycycline, advantageously covering other tick-borne infections such as Rocky Mountain spotted fever or anaplasmosis . Again, it should be noted that convalescent serology may be falsely negative in patients exposed to antibiotic treatment early in the course of Lyme disease .
This case series identifies several challenges faced by practitioners in high-risk communities, challenges which may not be apparent from patients selected for treatment trials, or in non-urgent, tertiary referral centers. Diagnosing Lyme disease continues to depend on experience with accurate identification of typical and atypical EM, and confirmatory testing in early Lyme disease continues to be problematic for community clinicians. Our experience suggests that a significant percentage of cases may show alternative presentations, resulting in inaccurate diagnosis and the use of ineffective antibiotics or steroids. Despite a recent emphasis on curbing over-diagnosis of Lyme disease, these findings suggest that in non-research settings of high-risk communities, the possibility of misdiagnosis may be underestimated by the medical community. Reliance on previous CDC criteria  for clinical diagnosis may lead to under-diagnosis of early cases, and community clinicians should be made aware both of recent guideline changes and their limitations in individual diagnosis. Awareness of recent CDC surveillance case definition diagnostic guideline changes  and their limitations, awareness of alternative clinical presentations, an appreciation for the varied manifestations of EM, and the appropriate use of serologic testing will be necessary to reverse this trend.
This study was supported in part by the Lyme Disease Research Foundation of Maryland. The authors would also like to thank Dr. Keith Kuhlemeier for help with database construction.
- Bacon RM, Kugeler KJ, Mead PS, Centers for Disease Control and Prevention: Surveillance for Lyme disease – United States, 1992–2006. MMWR Surveill Summ. 2008, 57: 1-9.PubMedGoogle Scholar
- Meek JI, Roberts CL, Smith EV, Cartter ML: Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manage Pract. 1996, 2: 61-5.View ArticleGoogle Scholar
- Coyle BS, Strickland GT, Liang YY, Pena C, McCarter R, Israel E: The public health impact of Lyme disease in Maryland. J Infect Dis. 1996, 173: 1260-2.View ArticlePubMedGoogle Scholar
- Wormser GP: Clinical practice. Early Lyme disease. N Engl J Med. 2006, 354: 2794-801. 10.1056/NEJMcp061181.View ArticlePubMedGoogle Scholar
- Tibbles CD, Edlow JA: Does this patient have erythema migrans?. JAMA. 2007, 297: 2617-27. 10.1001/jama.297.23.2617.View ArticlePubMedGoogle Scholar
- Feder HM, Whitaker DL: Misdiagnosis of erythema migrans. Am J Med. 1995, 99: 412-9. 10.1016/S0002-9343(99)80190-9.View ArticlePubMedGoogle Scholar
- Steere AC, Dhar A, Hernandez J, et al: Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. Am J Med. 2003, 114: 58-62. 10.1016/S0002-9343(02)01440-7.View ArticlePubMedGoogle Scholar
- Centers for Disease Control and Prevention: Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep. 1997, 46 (RR-10): 1-55.Google Scholar
- Lyme Disease (Borrelia burgdorferi) 2008 Case Definition, Centers for Disease Control and Prevention. [http://www.cdc.gov/ncphi/disss/nndss/casedef/lyme_disease_2008.htm]
- Centers for Disease Control and Prevention: Lyme disease – United States, 2003–2005. MMWR Morb Mortal Wkly Rep. 2007, 56: 573-6.Google Scholar
- Nowakowski J, McKenna D, Nadelman RB, et al: Failure of treatment with cephalexin for Lyme disease. Arch Fam Med. 2000, 9: 563-7. 10.1001/archfami.9.6.563.View ArticlePubMedGoogle Scholar
- Wormser GP, Dattwyler RJ, Shapiro ED, et al: The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006, 43: 1089-134. 10.1086/508667.View ArticlePubMedGoogle Scholar
- Lyme Disease Diagnosis, Centers for Disease Control and Prevention. [http://www.cdc.gov/ncidod/dvbid/lyme/ld_humandisease_diagnosis.htm]
- Magri JM, Johnson MT, Herring TA, Greenblatt JF: Lyme disease knowledge, beliefs, and practices of New Hampshire primary care physicians. J Am Board Fam Pract. 2002, 15: 277-84.PubMedGoogle Scholar
- Sigal LH: Toward a more complete appreciation of the clinical spectrum of Borrelia burgdorferi infection: early Lyme disease without erythema migrans. Am J Med. 2003, 114: 74-5. 10.1016/S0002-9343(02)01439-0.View ArticlePubMedGoogle Scholar
- Luft BJ, Dattwyler RJ, Johnson RC, et al: Azithromycin compared with amoxicillin in the treatment of Erythema Migrans. Annals of Internal Medicine. 1996, 124: 785-791.View ArticlePubMedGoogle Scholar
- Klempner MS: Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis. 2002, 2: 255-63. 10.1089/153036602321653842.View ArticlePubMedGoogle Scholar
- Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC: Evaluation of study patients with Lyme disease, 10–20-year follow-up. J Infect Dis. 2001, 183: 453-60. 10.1086/318082.View ArticlePubMedGoogle Scholar
- Shadick NA, Phillips CB, Sangha O, et al: Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med. 1999, 131: 919-26.View ArticlePubMedGoogle Scholar
- Cairns V, Godwin J: Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol. 2005, 34: 1340-5. 10.1093/ije/dyi129.View ArticlePubMedGoogle Scholar
- Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP: Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol. 2005, 34: 1437-9. 10.1093/ije/dyi241. author reply 1440-3View ArticlePubMedGoogle Scholar
- Sigal LH: Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med. 1990, 88: 577-81. 10.1016/0002-9343(90)90520-N.View ArticlePubMedGoogle Scholar
- Centers for Disease Control and Prevention: Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995, 44: 590-1.Google Scholar
- Coulter P, Lema C, Flayhart D, et al: Two-year evaluation of Borrelia burgdorferi culture and supplemental tests for definitive diagnosis of Lyme disease. J Clin Microbiol. 2005, 43: 5080-4. 10.1128/JCM.43.10.5080-5084.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Osterhoudt KC, Zaoutis T, Zorc JJ: Lyme disease masquerading as brown recluse spider bite. Ann Emerg Med. 2002, 39: 558-61. 10.1067/mem.2002.119509.View ArticlePubMedGoogle Scholar
- Rosenstein ED, Kramer N: Lyme disease misdiagnosed as a Brown Recluse spider bite. Ann of Internal Medicine. 1987, 107: 782-View ArticleGoogle Scholar
- Vetter RS, Bush SP: The diagnosis of brown recluse spider bite is overused for dermonecrotic wounds of uncertain etiology. Ann Emerg Med. 2002, 39: 544-6. 10.1067/mem.2002.123594.View ArticlePubMedGoogle Scholar
- Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP: Diagnosis of lyme borreliosis. Clin Microbiol Rev. 2005, 18: 484-509. 10.1128/CMR.18.3.484-509.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Steere AC, Sikand VK, Meurice F, et al: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med. 1998, 339: 209-15. 10.1056/NEJM199807233390401.View ArticlePubMedGoogle Scholar
- Belongia EA, Reed KD, Mitchell PD, et al: Tickborne infections as a cause of nonspecific febrile illness in Wisconsin. Clin Infect Dis. 2001, 32: 1434-9. 10.1086/320160.View ArticlePubMedGoogle Scholar
- Nowakowski J, Nadelman RB, Sell R, et al: Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med. 2003, 115: 91-6. 10.1016/S0002-9343(03)00308-5.View ArticlePubMedGoogle Scholar
- Wormser GP, Ramanathan R, Nowakowski J, et al: Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003, 138: 697-704.View ArticlePubMedGoogle Scholar
- Aguero-Rosenfeld M: Laboratory aspects of tick-borne diseases: lyme, human granulocytic ehrlichiosis and babesiosis. Mt Sinai J Med. 2003, 70: 197-206.PubMedGoogle Scholar
- Nadelman RB, Nowakowski J, Forseter G, et al: The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med. 1996, 100: 502-8. 10.1016/S0002-9343(95)99915-9.View ArticlePubMedGoogle Scholar
- Beck AS, Okulicz JF, Rasnake MS: Chest pain in a military recruit. South Med J. 2008, 101: 202-4.View ArticlePubMedGoogle Scholar
- Chen JP: Lyme carditis: another diagnostically elusive spirochetal disease. South Med J. 2008, 101: 125-6.View ArticlePubMedGoogle Scholar
- Halperin JJ: Is neuroborreliosis a medical emergency?. Neurocrit Care. 2006, 4: 260-6. 10.1385/NCC:4:3:260.View ArticlePubMedGoogle Scholar
- Kraiczy P, Weigand J, Wichelhaus TA, et al: In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother. 2001, 45: 2486-94. 10.1128/AAC.45.9.2486-2494.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP: Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol. 1996, 34: 1-9.PubMedPubMed CentralGoogle Scholar
- Halperin JJ, Shapiro ED, Logigian E, et al: Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007, 69: 91-102. 10.1212/01.wnl.0000265517.66976.28.View ArticlePubMedGoogle Scholar
- Bai Y, Narayan K, Dail D, et al: Spinal cord involvement in the nonhuman primate model of Lyme disease. Lab Invest. 2004, 84: 160-72. 10.1038/labinvest.3700024.View ArticlePubMedGoogle Scholar
- Nadelman RB, Wormser GP: Management of Tick Bites and Early Lyme Disease. Lyme Disease. Edited by: Rahn DW, Evans J. 1998, Philadelphia, PA, American College of Physicians, 49-75.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/9/79/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.